跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,185 条关于
“CAMCEVI ETM”
全部
1,185
临床试验
634
药物
342
机构
112
资讯
97
去年
FDA Approves Foresee's CAMCEVI ETM 21mg for Advanced Prostate Cancer Treatment
8个月前
Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera Therapeutics in $584.5 Million Deal
去年
DSMB Endorses Safety of Foresee's CAMCEVI in Pediatric Precocious Puberty Trial
去年
FDA Sets PDUFA Date for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer
去年
Foresee Pharmaceuticals Seeks FDA Approval for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer
去年
Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for Central Precocious Puberty Treatment
去年
Foresee Pharmaceuticals' Leuprolide (FP-001) Receives Positive DSMB Recommendation for CPP Phase 3 Trial
去年
FDA Reviews 3-Month Leuprolide Mesylate for Advanced Prostate Cancer
去年
Foresee Pharmaceuticals to Present Phase 3 KATANA Studies of Novel Prostate Cancer Treatment at ASCO-GU 2025
去年
Foresee Pharmaceuticals Submits NDA for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer
第 1 页,共 10 页
上一页
下一页